BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Argüelles-Arias F, Guerra Veloz MF, Perea Amarillo R, Vilches-Arenas A, Castro Laria L, Maldonado Pérez B, Chaaro Benallal D, Benítez Roldán A, Merino V, Ramirez G, Calleja-Hernández MA, Caunedo Álvarez A, Romero Gómez M. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol 2017;29:1290-5. [PMID: 28902041 DOI: 10.1097/MEG.0000000000000953] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Skup M, Yang M, Qi CZ, Wu EQ. Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018. Adv Ther 2022. [PMID: 35737227 DOI: 10.1007/s12325-022-02173-7] [Reference Citation Analysis]
2 Reinisch W, Cohen S, Ramchandani M, Khraishi M, Liu J, Chow V, Franklin J, Colombel JF. A Review of the Totality of Evidence for the Development and Approval of ABP 710 (AVSOLA), an Infliximab Biosimilar. Adv Ther 2022;39:44-57. [PMID: 34757601 DOI: 10.1007/s12325-021-01944-y] [Reference Citation Analysis]
3 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Abidin AZ, Snoswell CL, Shafiee Hanjani L, Callaghan G, Edmonds M. Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity. J Pharm Pract Res 2021;51:358-73. [DOI: 10.1002/jppr.1754] [Reference Citation Analysis]
5 Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis 2020;21:610-20. [PMID: 32920972 DOI: 10.1111/1751-2980.12940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Bernard EJ, Fedorak RN, Jairath V. Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci 2020;65:2354-72. [PMID: 31970610 DOI: 10.1007/s10620-019-06036-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
7 Strik AS, D'Haens GR, Löwenberg M. Hemolytic anemia after switching from infliximab originator to biosimilar CT-P13 in a patient with inflammatory bowel disease: A case report. Clin Case Rep 2019;7:2049-53. [PMID: 31788249 DOI: 10.1002/ccr3.2394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Guerra Veloz MF, Belvis Jiménez M, Valdes Delgado T, Castro Laria L, Maldonado Pérez B, Perea Amarillo R, Merino Bohórquez V, Caunedo Álvarez Á, Vilches Arenas Á, Argüelles-Arias F. Long-term follow up after switching from original infliximab to an infliximab biosimilar: real-world data. Therap Adv Gastroenterol 2019;12:1756284819858052. [PMID: 31258621 DOI: 10.1177/1756284819858052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
9 Meyer A, Rudant J, Drouin J, Coste J, Carbonnel F, Weill A. The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis. Aliment Pharmacol Ther 2019;50:269-77. [PMID: 31115919 DOI: 10.1111/apt.15323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
10 Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol 2019;12:1756284819842748. [PMID: 31019554 DOI: 10.1177/1756284819842748] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
11 Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther 2019;19:1031-43. [PMID: 30574813 DOI: 10.1080/14712598.2019.1561851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Guerra Veloz MF, Argüelles-Arias F, Castro Laria L, Maldonado Pérez B, Benítez Roldan A, Perea Amarillo R, Merino Bohórquez V, Calleja MA, Caunedo Álvarez Á, Vilches Arenas Á. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease. World J Gastroenterol 2018; 24(46): 5288-5296 [PMID: 30581277 DOI: 10.3748/wjg.v24.i46.5288] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
13 Plevris N, Jones GR, Jenkinson PW, Lyons M, Chuah CS, Merchant LM, Pattenden RJ, Watson EF, Ho GT, Noble CL, Din S, Shand AG, Arnott ID, Lees CW. Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Dig Dis Sci 2019;64:1660-7. [PMID: 30535885 DOI: 10.1007/s10620-018-5406-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
14 Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, Torp J, Grip O, Nilson S, Hertervig E, Lillienau J, Marsal J. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol 2018;11:1756284818801244. [PMID: 30344642 DOI: 10.1177/1756284818801244] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
15 Sieczkowska-Golub J, Jarzebicka D, Oracz G, Kierkus J. Biosimilars in paediatric inflammatory bowel disease. World J Gastroenterol 2018; 24(35): 4021-4027 [PMID: 30254406 DOI: 10.3748/wjg.v24.i35.4021] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
16 Numan S, Faccin F. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies. Adv Ther 2018;35:1295-332. [PMID: 30084060 DOI: 10.1007/s12325-018-0742-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
17 Strik AS, Dreesen E, Samaan M, Gecse K, Matheeuwsen M, Berends S, D'haens G. Effectiveness and safety of switching IBD patients from the originator to the biosimilar infliximab. Cochrane Database of Systematic Reviews 2018. [DOI: 10.1002/14651858.cd013068] [Reference Citation Analysis]
18 Gisbert JP, Chaparro M. Switching from an originator anti-TNF to a biosimilar in patients with inflammatory bowel disease: Can it be recommended? A systematic review. Gastroenterología y Hepatología (English Edition) 2018;41:389-405. [DOI: 10.1016/j.gastre.2018.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Scott FI, Lichtenstein GR. Biosimilars in the Treatment of Inflammatory Bowel Disease: Supporting Evidence in 2017. Curr Treat Options Gastroenterol 2018;16:147-64. [PMID: 29492747 DOI: 10.1007/s11938-018-0177-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
20 . Infliximab. Reactions Weekly 2017;1678:105-105. [DOI: 10.1007/s40278-017-38651-x] [Reference Citation Analysis]